American Association for Cancer Research
Browse
00085472can102386-sup-sfig_2.pdf (55.37 kB)

Supplementary Figure 2 from Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc-Induced Tumors

Download (55.37 kB)
journal contribution
posted on 2023-03-30, 20:49 authored by Kenichiro Fujiwara, Inez Yuwanita, Daniel P. Hollern, Eran R. Andrechek
Supplementary Figure 2 from Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc-Induced Tumors

History

ARTICLE ABSTRACT

Advances in genomic signatures have begun to dissect breast cancer heterogeneity and application of these signatures will allow the prediction of which pathways are important in tumor development. Here we used genomic signatures to predict involvement of specific E2F transcription factors in Myc-induced tumors. We genetically tested this prediction by interbreeding Myc transgenics with mice lacking various activator E2F alleles. Tumor latency decreased in the E2F1 mutant background and significantly increased in both the E2F2 and E2F3 mutants. Investigating the mechanism behind these changes revealed a reduction in apoptosis in the E2F1 knockout strain. E2F2 and E2F3 mutant backgrounds alleviated Myc proliferative effects on the pregnant mammary gland, reducing the susceptible tumor target population. Gene expression data from tumors revealed that the E2F2 knockout background resulted in fewer tumors with EMT, corresponding with a reduction in probability of Ras activation. In human breast cancer we found that a low probability of E2F2 pathway activation was associated with increased relapse-free survival time. Together these data illustrate the predictive utility of genomic signatures in deciphering the heterogeneity within breast cancer and illustrate the unique genetic requirements for individual E2Fs in mediating tumorigenesis in both mouse models and human breast cancer. Cancer Res; 71(5); 1924–32. ©2011 AACR.